Literature DB >> 15546109

Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US--an update.

Adolf W Karchmer1.   

Abstract

Three major North American surveillance programs have tracked antimicrobial resistance patterns among isolates of Streptococcus pneumoniae and other common respiratory tract pathogens. The Canadian Bacterial Surveillance Network shows the progressive increase in resistance among pneumococcal S. pneumoniae to penicillin, trimethoprim-sulfamethoxazole, macrolides, and fluoroquinolones. The data from the Tracking Resistance in the United States Today study also show a steady rise in pneumococcal resistance among common antibiotics as well as an increase in multidrug-resistant S. pneumoniae. The US component of the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study has detected increasing resistance to many antimicrobial agents among common respiratory isolates, with marked geographic variations in resistance patterns. The patterns of resistance detected by these major surveillance programs are a warning signal regarding the continued emergence of resistance among community-acquired respiratory tract pathogens.

Entities:  

Mesh:

Year:  2004        PMID: 15546109     DOI: 10.1086/421352

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  19 in total

1.  Trends in antibiotic resistance among respiratory tract pathogens in children in two regions near France, a high level resistance country.

Authors:  Reinhard Zbinden
Journal:  Eur J Pediatr       Date:  2005-08-30       Impact factor: 3.183

Review 2.  Novel approaches to developing new antibiotics for bacterial infections.

Authors:  A R M Coates; Y Hu
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

3.  Aggregation of Streptococcus pneumoniae by a pneumococcal capsular polysaccharide-specific human monoclonal IgM correlates with antibody efficacy in vivo.

Authors:  Kevin Fabrizio; Catherine Manix; Allan J Guimaraes; Joshua D Nosanchuk; Liise-Anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2010-03-03

4.  Trends in antibiotic resistance of respiratory tract pathogens in children in Geneva, Switzerland.

Authors:  Thomas Jaecklin; Peter Rohner; Véronique Jacomo; Kurt Schmidheiny; Alain Gervaix
Journal:  Eur J Pediatr       Date:  2005-08-25       Impact factor: 3.183

5.  Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.

Authors:  Kerry L LaPlante; Michael J Rybak; Brian Tsuji; Thomas P Lodise; Glenn W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  2007-02-12       Impact factor: 5.191

Review 6.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings.

Authors:  Carlos G Grijalva; J Pekka Nuorti; Marie R Griffin
Journal:  JAMA       Date:  2009-08-19       Impact factor: 56.272

8.  National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.

Authors:  Ian A Critchley; Steven D Brown; Maria M Traczewski; Glenn S Tillotson; Nebojsa Janjic
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

9.  International Circumpolar Surveillance System for invasive pneumococcal disease, 1999-2005.

Authors:  Michael G Bruce; Shelley L Deeks; Tammy Zulz; Dana Bruden; Christine Navarro; Marguerite Lovgren; Louise Jette; Karl Kristinsson; Gudrun Sigmundsdottir; Knud Brinkløv Jensen; Oistein Lovoll; J Pekka Nuorti; Elja Herva; Anders Nystedt; Anders Sjostedt; Anders Koch; Thomas W Hennessy; Alan J Parkinson
Journal:  Emerg Infect Dis       Date:  2008-01       Impact factor: 6.883

10.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.